Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × Spinal Puncture × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
8 enrolled 17 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡